MCK · 10-Q · 2026Q2 · Full report

Oncology Specialty Demand

MCKESSON CORP · 2026-08-05 · Importance 70 · Surprise 56 · In source text

Oncology & Multispecialty revenue increased 33% year over year to $14,222 million from $10,658 million in the three months ended June 30, 2026. The segment serves specialty-care markets through specialty drug distribution, infusion services, direct-to-patient pharmacy capabilities, cell and gene therapy services, vaccine distribution, and oncology practice solutions. It supports The U.S. Oncology Network, a large network of physician-led, integrated, community-based oncology practices in the U.S., as well as retina and ophthalmology providers through PRISM Vision. The segment also provides research, technology, and services through Sarah Cannon Research Institute and Ontada.

Key facts

• Oncology & Multispecialty revenues increased $3.6 billion or 33% for the three months ended June 30, 2026 compared to the same prior year period primarily driven by higher specialty pharmaceutical sales in provider solutions. source
• Oncology & Multispecialty segment revenues for the three months ended June 30, 2026: $14,222 million; for the three months ended June 30, 2025: $10,658 million. source
• Segment operating profit margin for Oncology & Multispecialty for the three months ended June 30, 2026: 2.29%; for the three months ended June 30, 2025: 1.99%. source
• Operating profit for the Oncology & Multispecialty segment increased for the three months ended June 30, 2026 primarily due to growth in specialty pharmaceuticals, including contributions from business acquisitions completed in the prior year, partially offset by increased operating expenses to support higher volumes. source

Impact estimates